Insight on Daiichi Sankyo’s ROS1/NTRK inhibitor DS-6051 licensing deal with AnHeart Therapeutics
Posted on19 Dec 2018
TagsAnHeart Therapeutics, Daiichi Sankyo, global pharma licensing deal, licensing deal in pharma, outlicensing in pharma
Comments0
Daiichi Sankyo and AnHeart Therapeutics announced they have entered into a worldwide exclusive license agreement for DS-6051, Daiichi Sankyo’s selective ROS1/NTRK inhibitor,... Read More